Blog
Health Canada Compliance Insights
NHPD testing guides, Canadian regulatory updates, and compliance insights for natural health product manufacturers, supplement brands, and Amazon Canada sellers.
Canada's Pharmaceutical Labs Are Understaffed — And GMP Auditors Are Starting to Notice
Canada's analytical chemist shortage isn't just an HR problem — it's creating real GMP compliance risks that Health Canada inspectors are flagging.
Health Canada's NOC/c Pathway: What Sponsors of Serious-Disease Drugs Need to Know Before Filing
Health Canada's NOC/c offers conditional drug approval for serious diseases, with binding post-market commitments. A practical guide for Canadian drug sponsors.
Beyond Health Canada Approval: How CADTH's HTA Process Determines Whether Canadians Can Access Your Drug
A Health Canada NOC is only the first gate. This guide explains CADTH's Common Drug Review, submission requirements, realistic timelines, and what sponsors consistently get wrong.
Decentralized Clinical Trials in Canada: What Health Canada's Guidance Actually Means for Sponsors and CROs
Health Canada permits DCTs under existing regulations — but protocol amendments, eConsent, and data integrity obligations are stricter than most sponsors expect.
Health Canada's Compendium of Monographs: Your Fastest Path to an NPN Under Canada's Natural Health Products Regulations
Learn how to use Health Canada's Compendium of Monographs to qualify for the faster Type I NPN pathway under Canada's Natural Health Products Regulations.
Forced Degradation Studies for Canadian Drug Submissions: What ICH Q1A and Health Canada Actually Require
Learn what Health Canada reviewers expect from forced degradation studies in Module 3 of your CTD, and the three mistakes that reliably delay NDS approval.
Pharmaceutical Water System Qualification Under Canada GMP: What Health Canada Inspectors Expect
What Health Canada GMP inspectors actually look for in pharmaceutical water system qualification — from three-phase PQ to alert limits, sanitization records, and change control.
ICH Q2(R2) Is Now Active: What Canadian Pharmaceutical Labs Need to Update in Their Analytical Validation Packages
ICH Q2(R2) is now active. Canadian pharma labs must update validation packages to meet new ATP and life cycle requirements for Health Canada GMP compliance.
GMP Quality Agreements for Contract Testing Laboratories in Canada: What Health Canada Actually Expects
Health Canada GMP inspectors routinely flag incomplete quality agreements with contract labs. Here's what every Canadian drug manufacturer must include.
Drug Serialization in Canada: The Traceability Requirements Your Pharma Supply Chain Cannot Ignore
Canada has no DSCSA equivalent yet — but Health Canada GMP, US export obligations, and hospital buyer pressure are closing the traceability gap fast.
Clinical Trial Application in Canada: How the CTA Process Works Under Division 5 of the Food and Drug Regulations
Learn how Canada's CTA process works under Division 5 of the Food and Drug Regulations — timelines, package requirements, and common NON-C triggers.
Canada GMP for Clinical Trial Materials: What Sponsors, CROs, and CMOs Need to Know
Health Canada's GMP requirements for clinical trial materials are stricter than most sponsors expect. Here's what the C.02 framework actually demands before you file a CTA.
Canada GMP's Qualified Person Responsible for Release: What Health Canada Expects From Your Lot Release Program
A deep dive into the QPRR role under Canada GMP regulations — C.02.014 requirements, qualifications, CMO considerations, and what Health Canada inspectors flag.
PBRER Submissions to Health Canada: What Drug Sponsors Get Wrong About Periodic Pharmacovigilance Reporting
Health Canada's PBRER requirements under ICH E2C(R2) differ meaningfully from FDA and EMA submissions. Here's what Canadian drug sponsors consistently miss.
Pharmacovigilance in Canada: What Drug Sponsors Must Report After Market Authorization
A practical guide to Health Canada pharmacovigilance obligations — adverse reaction timelines, PBRER requirements, and Vanessa's Law penalties for marketed drug sponsors.
CMO Qualification Audits Under Canada GMP: What to Verify Before You Outsource Manufacturing
Before outsourcing pharmaceutical manufacturing in Canada, you need a documented CMO qualification program. Here's what Health Canada GMP actually requires.
Schedule A Under Canada's Natural Health Products Regulations: The Disease Claim Rules That Keep Catching NPN Holders Off Guard
Schedule A of Canada's Food and Drugs Act prohibits disease claims on NHP labels and marketing. Here's what Canadian manufacturers keep getting wrong.
Cell and Gene Therapy Approval in Canada: What Health Canada's BGTD Pathway Actually Requires
A technical guide for sponsors developing cell and gene therapies in Canada — covering Health Canada's BGTD review pathway, GMP for viral vectors and autologous products, and realistic CTA-to-NOC timelines.